{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-24-000010","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.526434+00:00","generated_at":"2026-06-05T01:45:29.576400+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Werewolf Therapeutics reports Q4 2023 net loss $12M; CSO retiring March 29, 2024","bullets":["Net loss of $12.0M in Q4 2023 ($37.4M full year) vs $11.9M in Q4 2022.","Cash and equivalents $134.3M plus restricted cash $21.2M as of Dec 31, 2023.","Cash runway extended through Q2 2025, including $17.7M ATM proceeds in early 2024.","Collaboration revenue from Jazz fell to $1.5M Q4 from $7.3M year ago.","CSO Cynthia Seidel-Dugan retiring effective March 29, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-24-000010","json":"https://secwatch.observer/filing/0001785530-24-000010.json","markdown":"https://secwatch.observer/filing/0001785530-24-000010.md","text":"https://secwatch.observer/filing/0001785530-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/0001785530-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/howl-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:45:29.576400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3508f0c3b2e336e7b099e88c120c7f842b4b7583","claim":"Werewolf Therapeutics, Inc. reported quarter ended December 31, 2023 results: revenue $1.5 million.","evidence_excerpt":"Collaboration revenue was $1.5 million for the fourth quarter of 2023, compared to $7.3 million for the same period in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/0001785530-24-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended December 31, 2023"},{"label":"Revenue","value":"$1.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4374bf7160","claim":"Cynthia Seidel-Dugan departed as Chief Scientific Officer at Werewolf Therapeutics, Inc..","evidence_excerpt":"On March 3, 2024, Cynthia Seidel-Dugan, Ph.D., notified the Company of her intent to retire from her position as Chief Scientific Officer of the Company, effective as of March 29, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000010/0001785530-24-000010-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}